Deals in Depth: October 2009
Executive Summary
Sanofi-Aventis was the standout in pharma alliances, penning three of the big deals, which together were worth over $1 billion in potential deal value. Onyx's buy of cancer and immunology biotech Proteolix topped the M&A chart at $851 million. In devices, notable was Kimberly-Clark, which followed up last month's Baylis acquisition with another in pain management--I-Flow, for $309 million, over twice that company's sales. Almost 40% of pharma financing came from Talecris' $600 million notes offering. And fundraising for the device industry was boosted by an $88 million IPO completed by AGA Medical Holdings, and a $55 million Series B from TransEnterix.